Skip to main content

Table 1 Studies included in the meta-analysis

From: The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data

Study a

Number of patients treated with AS-AQ

Country

Age range (months)

Target dose (mg/kg) for artesunate & amodiaquine

Manufacturer

Formulation

Supervision

Reference

Adjuik-2002

390

Multicentric

6-59

12 & 30

Sanofi-Synthélabo & Parke-Davis

Loose NFDC

Full

[8]

Anvikar-2012 b

199

India

6-720

12 & 30

Sanofi-Aventis

FDC

Full

[36]

Barennes-2004

32

Burkina Faso

12-180

12 & 30

Sanofi Winthrop AMO & Hoechst Marion Roussel

Loose NFDC

Full

[64]

Bonnet-2007

110

Guinea

6-59

12 & 30

Guilin Pharmaceutical & Parke-Davis

Loose NFDC

Full

[65]

Brasseur-2009 b

276

Senegal

All ages

N/A

Sanofi-Aventis

Co-blistered NFDC

Full/partiale

[17]

Bukirwa-2006

203

Uganda

12-120

12 & 25

Sanofi-Aventis & Parke-Davis, Pfizer

Loose NFDC

Full

[66]

Dorsey-2007

145

Uganda

12-120

12 & 25

Sanofi-Aventis & Pfizer

Loose NFDC

Full

[67]

Espié-2012

149

DRC

6-59

12 & 30

Sanofi-Aventis

FDC

Full

[34]

Faucher-2009

94

Benin

6-60

12 & 30

Sanofi-Aventis

FDC

Partial

[68]

Faye-2010

155

Multicentric

>84

N/A

Pfizer

Co-blistered NFDC

Full

[69]

Gaye-2010b d

129

Senegal

12-720

12 & 30

Sanofi-Aventis

FDC

Full

[Unpublished]

Grandesso-2003 d

86

Uganda

6-59

12 & 30

Sanofi & Park-Davis

Loose NFDC

Full

[Unpublished]

Grandesso-2006

123

Sierra Leone

6-59

12 & 30

Sanofi Winthrop AMO & Pfizer

Loose NFDC

Full

[44]

Guthmann-2005

96

Angola

6-59

12 & 30

Sanofi Winthrop & Parke Davis

Loose NFDC

Full

[70]

Guthmann-2006

68

Angola

6-59

12 & 30

Sanofi Winthrop & Parke Davis

Loose NFDC

Full

[71]

Hamour-2005

71

Sudan

6-59

12 & 30

Sanofi & Park-Davis

Loose NFDC

Full

[72]

Hasugian-2007

93

Indonesia

>12

12 & 30

Guilin Pharmaceuticals & Aventis

Loose NFDC

Full

[6]

Jullien-2010

27

Kenya

216-720

N/A

Sanofi-Aventis

Co-blistered NFDC

Full

[73]

Jullien-2010

24

Kenya

216-720

12 & 30

Sanofi-Aventis

FDC

Full

[73]

Juma-2005 d

201

Kenya

6-59

12 & 30

Sanofi-Aventis

Loose NFDC

Full

[Unpublished]

Karema-2006

251

Rwanda

12-59

12 & 30

Sanofi-Aventis

Loose NFDC

Full

[74]

Kayentao-2009

128

Mali

6-59

12 & 30

-

Co-blistered NFDC

Full

[75]

Laminou-2011 d

80

Niger

6-180

12 & 30

Sanofi-Aventis

FDC

Partial

[Unpublished]

MÃ¥rtensson-2005

202

Tanzania

6-59

12 & 30

Mepha & Roussel

Loose NFDC

Full

[45]

Menan-2012 d

110

Ivory Coast

12-480

12 & 30

Sanofi-Aventis

FDC

Full

[Unpublished]

Menard-2008

332

Madagascar

6-180

12 & 30

-

Loose NFDC

Full

[76]

Ndiaye-2009

625

Multicentric

All ages

12 & 30

Sanofi-Aventis

FDC

Full

[30]

Ndiaye-2011

179

Senegal

All ages

12 & 30

Sanofi-Aventis

FDC

Fullf

[32]

Nikiema-2010 d

527

Burkina Faso

6-120

12 & 30

Sanofi-Aventis

FDC

Full

[Unpublished]

Osorio-2007

37

Columbia

12-780

12 & 30

Sanofi-Aventis

Loose NFDC

Full

[77]

Rwagacondo-2004

157

Rwanda

6-59

12 & 30

Dafra

Loose NFDC

Full

[11]

Sagara-2012

230

Mali

≥6

12 & 30

Sanofi-Aventis

Co-blistered NFDC

Full

[78]

Sanofi-2013 d

203

Uganda

6-59

12 & 30

Sanofi-Aventis

FDC

Fullf

[Unpublished]

Schramm-2013

147

Liberia

6-72

12 & 30

Sanofi-Aventis

FDC

Full

[38]

Sinou-2009 c

13

Congo

≥192

12 & 30

Saokim Pharmaceuticals Co

FDC

Full

[31]

Sirima-2009 b

441

Burkina Faso

6-59

12 & 30

Sanofi-Aventis

Co-blistered NFDC

Full

[18]

Sirima-2009 b

437

Burkina Faso

6-59

12 & 30

Sanofi-Aventis

FDC

Full

[18]

Smithuis-2010

142

Myanmar

>6

12 & 32/4

Sanofi-Aventis

FDC

Partial

[7]

Staedke-2004

130

Uganda

6-120

12 & 25

Sanofi-Pfizer

Loose NFDC

Full

[79]

Swarthout-2006

82

DRC

6-59

12 & 30

Sanofi and Parke Davis & Pfizer

Loose NFDC

Full

[80]

Temu-2010 d

99

Liberia

6-60

12 & 30

Sanofi-Aventis

FDC

Full

[Unpublished]

The 4ABC StudyGroup-2011

981

Multicentric

6-59

12 & 30

Sanofi-Aventis

FDC

Full

[15]

Thwing-2009

101

Kenya

6-59

12 & 25

Cosmo Pharmaceuticals & Pfizer

Loose NFDC

Full

[46]

van den Broek-2006

87

Congo

6-59

12 & 30

Cosmo Pharmaceuticals & Pfizer

Loose NFDC

Full

[81]

Yeka-2005

714

Uganda

≥6

12 & 25

Sanofi-Pfizer

Loose NFDC

Full

[82]

  1. aFull details of the references and study design are available in Additional file 1: Text S1.
  2. bThe dose was given based on age bands for these studies. For the rest of the studies, dosing was based on weight categories.
  3. cAll patients recruited given 2 doses/day.
  4. dThese studies are unpublished.
  5. eFully supervised between 2002-2004 and partially supervised in 2005.
  6. fThe first episodes of malaria were fully supervised in these studies.